[HTML][HTML] A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
EA Feitsma, YF Janssen, HH Boersma… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
[HTML][HTML] A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
EA Feitsma, YF Janssen, HH Boersma, Y van Sleen… - Vaccine, 2023 - ncbi.nlm.nih.gov
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
E Feitsma, Y Janssen, H Boersma, Y van Sleen… - Vaccine, 2023 - europepmc.org
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
EA Feitsma, YF Janssen, HH Boersma, Y van Sleen… - 2023 - cabidigitallibrary.org
Background: Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
EA Feitsma, YF Janssen, HH Boersma, Y van Sleen… - Vaccine, 2023 - research.rug.nl
Background: Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
EA Feitsma, YF Janssen, HH Boersma, Y van Sleen… - Vaccine, 2023 - europepmc.org
Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …